Navigation Links
Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
Date:5/2/2011

patents to be issued during 2011.  At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be compl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
3. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
4. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
5. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
6. Silence Therapeutics Appoints New Vice President of Research
7. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Once ... to provide a larger packaged waste water treatment plant ... King Abdullah Economic City (KAEC). Two years ago Bioshaft ... Jeddah Gate Development, serving two residential towers with an ... is over a quarter million gallons per day and ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... at the American Society of Clinical Oncology (ASCO) annual meeting, ... Today at 5:00 p.m. Eastern Time - REDWOOD CITY, Calif., ... ) today announced that the QUASAR validation study met ... stage II colon cancer patients following surgery, and that the ...
... at 2:00 p.m. PT (5:00 p.m. ET)IRVINE, Calif., April 14 ... of Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, ... for the period ended April 4, 2009 after the market ... the results will begin at 2:00 p.m. PT (5:00 p.m. ...
... and New Vice President of Healthcare Brings 22 ... Ore., April 14 Prolifiq Software, Inc., today ... company as vice president of healthcare. In this ... mobile email messaging services for sales representatives in ...
Cached Biology Technology:Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 4Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 2Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 3Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 2Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 3
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... most school children understand that green plants photosynthesize, ... consider the profound global-scale effects that photosynthesis has ... light on the origins and evolution of photosynthesis ... University,s School of Life Sciences. Oxygen, one ...
... CLEVELAND Case Western Reserve University has granted ... regarding a portfolio of insulin analogs. The company must ... to obtain an exclusive license on therapies designed to ... developing treatments that it hopes will become an important ...
... discoveries about the deep ocean,s temperature variability and circulation ... The deep ocean is affected more by surface ... more accurate predictions of factors such as sea level ... temperatures have also been found to result in a ...
Cached Biology News:'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2New discoveries could improve climate projections 2
ID clarifier: platform...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
Biology Products: